|
Potential of Resveratrol in Cardiovascular Disorders – A Systematic Review
|
Jaskomal Phagoora *    , Mark Wanis , Brett Agrest , Moshe Kabariti , Domaldy Dejesus , Arshia Hamzehpour , Sukhpreet Saini , Agha Abbas , Jisha Reji , Sarthak Bakilwal |
| Touro College of Osteopathic Medicine , jaskomalphagoora@gmail.com |
|
|
Abstract: (232 Views) |
Background and Objectives: Cardiovascular diseases (CVDs) are the leading cause of global mortality, responsible for 17.9 million deaths annually. Antioxidants like resveratrol (RES), a polyphenolic compound found in grapes and red wine, have gained attention for their potential cardioprotective effects. This review synthesizes existing research on resveratrol's impact on various cardiovascular conditions, including atherosclerosis, coronary artery disease (CAD), hypertension, cardiac remodeling, stroke, myocardial ischemia, heart failure, and Chagas heart disease.
Materials and Methods: A systematic review was conducted, analyzing studies from January 1991 to August 2024. Databases searched included PubMed, Scopus, and Web of Science, focusing on randomized controlled trials, meta-analyses, and systematic reviews involving both human and animal subjects. Data were extracted on study design, treatment protocols, cardiovascular outcomes, and adverse effects.
Results: Resveratrol exhibits significant cardioprotective effects, primarily through its antioxidant and anti-inflammatory properties. It reduces oxidative stress, mitigates endothelial dysfunction, and decreases inflammation, contributing to the prevention and management of atherosclerosis, CAD, hypertension, and myocardial ischemia. Additionally, resveratrol shows promise in improving stroke outcomes, enhancing cardiac function in heart failure, and managing Chagas heart disease. However, bioavailability challenges remain a barrier to its therapeutic efficacy.
Conclusions: Resveratrol holds promise as a natural therapeutic agent for various cardiovascular diseases. While preclinical evidence is strong, more large-scale human trials are needed to confirm its clinical applicability. Addressing bioavailability issues could further enhance its potential as a treatment option in cardiovascular care.
|
|
| Keywords: Resveratrol, Atherosclerosis, Coronary artery disease |
|
|
Full-Text [PDF 963 kb]
(194 Downloads)
|
Article type: Review |
Subject:
Nutrition
Received: 2024/04/19 | Accepted: 2024/09/3 | Published: 2024/10/13
|
|
|
|
- Resveratrol has been shown to lower LDL cholesterol and triglycerides while increasing HDL cholesterol
- Resveratrol promotes nitric oxide (NO) production, leading to vasodilation and reduced blood pressure.
- Resveratrol has shown promise in reducing cardiac fibrosis, inhibiting ventricular hypertrophy, and improving overall cardiac function
- Resveratrol offers potential therapeutic benefits for ischemic stroke patients by reducing inflammation, promoting neurogenesis and angiogenesis.
- Resveratrol has been effective in reducing oxidative stress and improving cardiac function in Chagas heart disease.
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
